Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy
Descripción del Articulo
Background: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of re...
Autores: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | artículo |
Fecha de Publicación: | 2019 |
Institución: | Instituto Nacional de Enfermedades Neoplásicas |
Repositorio: | INEN-Institucional |
Lenguaje: | inglés |
OAI Identifier: | oai:repositorio.inen.sld.pe:inen/116 |
Enlace del recurso: | https://repositorio.inen.sld.pe/handle/inen/116 |
Nivel de acceso: | acceso abierto |
Materia: | RCB TILs TNBC neoadjuvant prognosis https://purl.org/pe-repo/ocde/ford#3.02.21 |
id |
INEN_4baeb0b029777ad4e17f216288e16b5a |
---|---|
oai_identifier_str |
oai:repositorio.inen.sld.pe:inen/116 |
network_acronym_str |
INEN |
network_name_str |
INEN-Institucional |
repository_id_str |
. |
spelling |
Luen, SJSalgado, RDieci, MVVingiani, ACurigliano, GGould, RECastaneda, CD'Alfonso, TSanchez, JCheng, EAndreopoulou, ECastillo, MAdams, SDemaria, SSymmans, WFMichiels, SLo,i S2024-07-01T16:28:49Z2024-07-01T16:28:49Z2019Background: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of residual disease (RD) TILs to residual cancer burden (RCB) in predicting survival post-NAC. Patients and methods: We combined four TNBC NAC patient cohorts who did not achieve pCR. RD TILs were investigated for associations with recurrence-free survival (RFS), and overall survival (OS) using Cox models with stromal TILs as a continuous variable (per 10% increment). The likelihood ratio test was used to evaluate added prognostic value of RD TILs. Results: A total of 375 RD TNBC samples were evaluable for TILs and RCB. The median age was 50 years, with 62% receiving anthracycline/taxane chemotherapy. The RCB class after NAC was 11%, 50%, and 39% for I, II, and III, respectively. The median RD TIL level was 20% (IQR 10-40). There was a positive correlation between RD TIL levels and CD8+ T-cell density (ρ = 0.41). TIL levels were significantly lower with increasing post-NAC tumor (P = 0.005), nodal stage (P = 0.032), but did not differ by RCB class (P = 0.84). Higher RD TILs were significantly associated with improved RFS (HR: 0.86; 95% CI 0.79-0.92; P < 0.001), and improved OS (HR: 0.87; 95% CI 0.80-0.94; P < 0.001), and remained significant predictors in multivariate analysis (RFS P = 0.032; OS P = 0.038 for OS). RD TILs added significant prognostic value to multivariate models including RCB class (P < 0.001 for RFS; P = 0.021 for OS). The positive prognostic effect of RD TILs significantly differed by RCB class for RFS (PInt=0.003) and OS (PInt=0.008) with a greater magnitude of positive effect observed for RCB class II than class III. Conclusions: TIL levels in TNBC RD are significantly associated with improved RFS and OS and add further prognostic information to RCB class, particularly in RCB class II.application/pdf10.1093/annonc/mdy547https://repositorio.inen.sld.pe/handle/inen/116engAnn OncolUKElsevier Ltd.info:eu-repo/semantics/openAccessdc.rights.uri: https//creativecomons.org/licenses/by/4.0/RCBTILsTNBCneoadjuvantprognosishttps://purl.org/pe-repo/ocde/ford#3.02.21Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapyinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:INEN-Institucionalinstname:Instituto Nacional de Enfermedades Neoplásicasinstacron:INENPublicationORIGINALLuen 2019.pdfapplication/pdf399195https://repositorio.inen.sld.pe/bitstreams/6a922ee9-df48-441e-90cc-3092baed1146/download5ce8ca6e5db978a19c1b3e8e3ee1b974MD51TEXTLuen 2019.pdf.txtLuen 2019.pdf.txtExtracted texttext/plain33097https://repositorio.inen.sld.pe/bitstreams/b5379036-c7da-4aa6-829a-7f5f5f9403a6/downloadd5ff1fb9d6d0e1588ced8d4eaa0a29a2MD52THUMBNAILLuen 2019.pdf.jpgLuen 2019.pdf.jpgGenerated Thumbnailimage/jpeg4914https://repositorio.inen.sld.pe/bitstreams/24259e29-fdab-455e-a637-656114df9c68/downloadd8faf3c97a068f17a9ddaeb6e0455f15MD53inen/116oai:repositorio.inen.sld.pe:inen/1162024-10-23 18:10:05.355dc.rights.uri: https//creativecomons.org/licenses/by/4.0/info:eu-repo/semantics/openAccesshttps://repositorio.inen.sld.peRepositorio INENrepositorioinendspace@gmail.com |
dc.title.none.fl_str_mv |
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy |
title |
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy |
spellingShingle |
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy Luen, SJ RCB TILs TNBC neoadjuvant prognosis https://purl.org/pe-repo/ocde/ford#3.02.21 |
title_short |
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy |
title_full |
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy |
title_fullStr |
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy |
title_full_unstemmed |
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy |
title_sort |
Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy |
author |
Luen, SJ |
author_facet |
Luen, SJ Salgado, R Dieci, MV Vingiani, A Curigliano, G Gould, RE Castaneda, C D'Alfonso, T Sanchez, J Cheng, E Andreopoulou, E Castillo, M Adams, S Demaria, S Symmans, WF Michiels, S Lo,i S |
author_role |
author |
author2 |
Salgado, R Dieci, MV Vingiani, A Curigliano, G Gould, RE Castaneda, C D'Alfonso, T Sanchez, J Cheng, E Andreopoulou, E Castillo, M Adams, S Demaria, S Symmans, WF Michiels, S Lo,i S |
author2_role |
author author author author author author author author author author author author author author author author |
dc.contributor.author.fl_str_mv |
Luen, SJ Salgado, R Dieci, MV Vingiani, A Curigliano, G Gould, RE Castaneda, C D'Alfonso, T Sanchez, J Cheng, E Andreopoulou, E Castillo, M Adams, S Demaria, S Symmans, WF Michiels, S Lo,i S |
dc.subject.none.fl_str_mv |
RCB TILs TNBC neoadjuvant prognosis |
topic |
RCB TILs TNBC neoadjuvant prognosis https://purl.org/pe-repo/ocde/ford#3.02.21 |
dc.subject.ocde.none.fl_str_mv |
https://purl.org/pe-repo/ocde/ford#3.02.21 |
description |
Background: For primary triple-negative breast cancer (TNBC) treated with neoadjuvant chemotherapy (NAC), higher pretreatment tumor-infiltrating lymphocytes (TILs) correlates with increased pathologic complete response (pCR) rates, and improved survival. We evaluated the added prognostic value of residual disease (RD) TILs to residual cancer burden (RCB) in predicting survival post-NAC. Patients and methods: We combined four TNBC NAC patient cohorts who did not achieve pCR. RD TILs were investigated for associations with recurrence-free survival (RFS), and overall survival (OS) using Cox models with stromal TILs as a continuous variable (per 10% increment). The likelihood ratio test was used to evaluate added prognostic value of RD TILs. Results: A total of 375 RD TNBC samples were evaluable for TILs and RCB. The median age was 50 years, with 62% receiving anthracycline/taxane chemotherapy. The RCB class after NAC was 11%, 50%, and 39% for I, II, and III, respectively. The median RD TIL level was 20% (IQR 10-40). There was a positive correlation between RD TIL levels and CD8+ T-cell density (ρ = 0.41). TIL levels were significantly lower with increasing post-NAC tumor (P = 0.005), nodal stage (P = 0.032), but did not differ by RCB class (P = 0.84). Higher RD TILs were significantly associated with improved RFS (HR: 0.86; 95% CI 0.79-0.92; P < 0.001), and improved OS (HR: 0.87; 95% CI 0.80-0.94; P < 0.001), and remained significant predictors in multivariate analysis (RFS P = 0.032; OS P = 0.038 for OS). RD TILs added significant prognostic value to multivariate models including RCB class (P < 0.001 for RFS; P = 0.021 for OS). The positive prognostic effect of RD TILs significantly differed by RCB class for RFS (PInt=0.003) and OS (PInt=0.008) with a greater magnitude of positive effect observed for RCB class II than class III. Conclusions: TIL levels in TNBC RD are significantly associated with improved RFS and OS and add further prognostic information to RCB class, particularly in RCB class II. |
publishDate |
2019 |
dc.date.accessioned.none.fl_str_mv |
2024-07-01T16:28:49Z |
dc.date.available.none.fl_str_mv |
2024-07-01T16:28:49Z |
dc.date.issued.fl_str_mv |
2019 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/article |
dc.type.version.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.doi.none.fl_str_mv |
10.1093/annonc/mdy547 |
dc.identifier.uri.none.fl_str_mv |
https://repositorio.inen.sld.pe/handle/inen/116 |
identifier_str_mv |
10.1093/annonc/mdy547 |
url |
https://repositorio.inen.sld.pe/handle/inen/116 |
dc.language.iso.none.fl_str_mv |
eng |
language |
eng |
dc.relation.ispartof.none.fl_str_mv |
Elsevier Ltd. |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
dc.rights.uri.none.fl_str_mv |
dc.rights.uri: https//creativecomons.org/licenses/by/4.0/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
dc.rights.uri: https//creativecomons.org/licenses/by/4.0/ |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Ann Oncol |
dc.publisher.country.none.fl_str_mv |
UK |
publisher.none.fl_str_mv |
Ann Oncol |
dc.source.none.fl_str_mv |
reponame:INEN-Institucional instname:Instituto Nacional de Enfermedades Neoplásicas instacron:INEN |
instname_str |
Instituto Nacional de Enfermedades Neoplásicas |
instacron_str |
INEN |
institution |
INEN |
reponame_str |
INEN-Institucional |
collection |
INEN-Institucional |
bitstream.url.fl_str_mv |
https://repositorio.inen.sld.pe/bitstreams/6a922ee9-df48-441e-90cc-3092baed1146/download https://repositorio.inen.sld.pe/bitstreams/b5379036-c7da-4aa6-829a-7f5f5f9403a6/download https://repositorio.inen.sld.pe/bitstreams/24259e29-fdab-455e-a637-656114df9c68/download |
bitstream.checksum.fl_str_mv |
5ce8ca6e5db978a19c1b3e8e3ee1b974 d5ff1fb9d6d0e1588ced8d4eaa0a29a2 d8faf3c97a068f17a9ddaeb6e0455f15 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio INEN |
repository.mail.fl_str_mv |
repositorioinendspace@gmail.com |
_version_ |
1841803064183357440 |
score |
12.87381 |
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).